Pacritinib/Strong CYP3A4 Inhibitors that Prolong QT Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may slow down how quickly your body processes pacritinib. Pacritinib can also affect your heart's rhythm. Your medicine can have the same effect.
What might happen:
The amount of pacritinib in your blood may increase and cause more side effects than expected. Some expected side effects may be more severe than expected.Taking pacritinib with other agents that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change your medicine.Get medical care right away if you experience discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back; severe tightness, pain, pressure, heaviness in your chest, throat, neck or jaw; shortness of breath; cold sweats; nausea; vomiting; lightheadedness; weakness in one part or one side side of your body; slurred speech; fainting; or rapid, fast, or irregular heartbeat.Tell your doctor right away if you have unusual bleeding or bruising, severe diarrhea, swelling or pain in your legs, or symptoms of an infection (such as fever, chills, and aches).Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Vonjo (pacritinib) US prescribing information. CTI BioPharmca Corp. Feb, 2022.
- 2.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and- drug-interactions-table-substrates-inhibitors-and-inducers. Updated 11/14/2017.
- 4.This information is based on an extract from the Certara Drug Interaction Database (DIDB) Platform, Copyright Certara 1999-2023..
- 5.USDepartment of Health and Human Services Food and Drug Administration. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: https://www.fda.gov/media/71372/download October, 2005.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.